- Lobbying
- Lobbying by National Resilience, Inc.
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Remy Brim | Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren See prior filing Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz |
Brent Del Monte | Leg. Dir. Rep. Bliley; Sen. Counsel House Energy & Commerce Committee Leg. Dir. Rep. Bliley; Sen. Counsel House Energy & Commerce Committee See prior filing |
John Stone | Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee See prior filing Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C |
Joel Bailey | COS Rep. Panetta; LD Rep. Ashford; LD Rep. Matheson; Sr. LA Rep. Matsui; LA / Sr. LA Rep. Baron Hill COS Rep. Panetta; LD Rep. Ashford; LD Rep. Matheson; Sr. LA Rep. Matsui; LA, Sr. LA Rep. Baron Hill; Intern Rep. Rahall |
Jennifer Lukawski | Leg. Dir. Rep. Dornan, Ex. Dir., U.S. House Con. Act. Team (Rep. Study Comm.); Intern, Staff Asst. Rep. Courter |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Q1 Report
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Office of Science & Technology Policy (OSTP)
Natl Security Council (NSC)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Office of Science & Technology Policy (OSTP)
Natl Security Council (NSC)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: Provide guidance and strategic counsel on issues impacting pharmaceutical manufacturing generally, and National Resilience, Inc. specifically..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate